Dividend Amount is $1.496675 per Outstanding Share of Merrimack Common Stock and Will be Paid Today, as Previously Announced Company Provides Update on NOL Carryforwards; No Impairment as of July 24, 2019 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 5, 2019-- Merrimack Pharmaceuticals (Nasdaq: MACK)
Company’s Board has Taken Crucial Actions to Maximize Shareholder Value and Preserve More than $500 Million in Potential Future Milestone Payments Merrimack’s Current Plan Follows Comprehensive Strategic Review Conducted with Leading Healthcare Financial Advisory Firm and Provides Best Pathway for
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 16, 2019-- Merrimack Pharmaceuticals (Nasdaq: MACK) (the “Company” or “Merrimack”) announced today it is rescheduling its 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”) for October 17, 2019 . As a result, the record date for the 2019 Annual
CAMBRIDGE, Mass. , July 25, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that its Board of Directors has authorized and declared a special cash dividend of $20 million on the Company's common stock. The special dividend is payable on September 5, 2019 to
CAMBRIDGE, Mass. , May 30, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the completion of its review of strategic alternatives, following which the Company's Board of Directors is implementing a series of measures designed to extend Merrimack's cash runway
CAMBRIDGE, Mass. , May 10, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), an oncology company focused on biomarker-defined cancers, today announced its first quarter 2019 financial results for the period ended March 31, 2019 . "We continue to focus our efforts on completing
-- Safety update shows Phase 1 study unable to reach optimal therapeutic index for MM-310 due to continued observation of cumulative peripheral neuropathy -- -- Company expects to reduce workforce reflective of narrowed preclinical development pipeline; continues to prudently advance programs while
CAMBRIDGE, Mass. , March 6, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its fourth quarter and full year 2018 financial results for the period ended December 31, 2018 .
- Company to initiate corporate restructuring, including ~60% reduction in force and significant reduction in operating expenses; potential to extend runway into at least 2H 2022 to preserve ability to capture Ipsen milestones - - Has engaged external advisors to evaluate strategic alternatives - -
CAMBRIDGE, Mass. , Oct. 31, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its third quarter 2018 investor conference call and webcast at 8:30 am ET on Wednesday, November 7, 2018. The call will provide an update on Merrimack's
